Drug Trial Radar · NCT06825416
A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,165
Actual
Start
Mar 16, 2025
Primary completion
Feb 15, 2026
Study completion Apr 23, 2026
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.
Conditions
- Prevention of Arterial and Venous Thrombosis
Interventions
SHR-2004 injectionDrug
SHR-2004 injection in low dose.
SHR-2004 injectionDrug
SHR-2004 injection in high dose.
Enoxaparin sodium injectionDrug
Enoxaparin sodium injection.
Enoxaparin sodium injection placeboDrug
Enoxaparin sodium injection placebo.
SHR-2004 placeboDrug
SHR-2004 placebo in low dose.
SHR-2004 placeboDrug
SHR-2004 placebo in high dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of asymptomatic deep vein thrombosis (DVT)Time frame: Day 12.
- Incidence of non-fatal pulmonary embolism (PE)Time frame: Day 12.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fourth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.